Treatment Advances for Challenging Patients with Type 2 Diabetes: What Managed Care Needs to Know About Fixed-Ration Combinations of Basal Insulin and GLP-1

A continuing medical education activity sponsored by NAMCP and AAMCN

These are archives of live webinars held between May 13 to May 28, 2020.
If you participated in any of the live webinars, you are not eligible
to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

These activities are valid from June 1, 2020 to June 1, 2022

Each session has its own specific valid dates

This series is supported by an educational grant from
Sanofi US

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
The ADA estimates that more than 30.3 million people in the US have diabetes. About 90-95% of adults who have diabetes have type 2 diabetes. According to the CDC, uncontrolled type 2 diabetes (T2DM) doubles a person's risk for death, and on average individuals with T2DM lose 10-15 years of life. The management of T2DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in T2DM management have given HCPs the ability to shrink this clinical practice gap. Fixed-ratio combinations of basal insulin and GLP-1 agonists have shown to improve both clinical and economic outcomes in T2DM patients, especially in challenging cases.

A Deeper Look into Fixed-Ratio Combinations of Basal Insulin and GLP-1 Receptor Agonists: What Does the Data Have to Say?

1. Quantify the clinical and economic burden of type 2 diabetes, including factors that contribute to poor patient adherence and increased costs
2. Examine evidence supporting the use of fixed-ratio GLP-1RA/basal insulin combinations as a means to overcome barriers to achieving glycemic control
3. Assess the role of fixed-ratio GLP-1RA/basal insulin combination therapies in management, particularly as it relates to more complicated T2DM patients
4. Discuss strategies to overcome barriers to the introduction and intensification of fixed-ratio therapies

What Managed Care Needs to Know about Reducing Healthcare Costs with Fixed-Ratio Combinations of Basal Insulin and GLP-1 Receptor Agonists

1. Quantify the economic burden of type 2 diabetes, including factors that contribute to poor patient adherence and increased costs
2. Examine the managed care considerations of fixed-ratio GLP-1RA/basal insulin combinations by exploring where these agents fit into current the type 2 diabetes management paradigm
3. Transform therapeutic advances in fixed-ratio combinations and resource utilization data into informed health plan decisions and formulary discussions for managed care professionals
4. Review recent clinical data on fixed-ratio GLP-1RA/basal insulin combinations

Improving Patient Adherence and Quality of Life in Challenging Patients with Type 2 Diabetes: Anticipating and Managing Adverse Events Associated with Basal Insulin and GLP-1 Receptor Agonists

1. Explore challenges to patient adherence and quality of life in challenging patients in type 2 diabetes
2. Review recent clinical data around the safety of fixed-ratio GLP-1RA/basal insulin combination therapies and their effect on patient quality of life
3. Analyze strategies to monitor and manage adverse events associated with fixed-ratio GLP-1RA/basal insulin combination therapies in type 2 diabetes management in order to improve patient adherence
4. Discuss strategies to overcome barriers to the introduction and intensification of fixed-ratio therapies